NSI-189

NSI-189

NSI-189 is a novel antidepressant developed by Neuralstem, Inc. It is a new class of compound referred to as a neurogenic compound, specifically designed to promote neurogenesis in the hippocampus, a region of the brain believed to be contributory in conditions such as depression and Alzheimer's disease.

History

Neuralstem, Inc. began the development of NSI-189 in the early 2000s, with the aim of creating a drug that could stimulate the growth of new neurons in the brain. The compound was first tested in animal models before progressing to human clinical trials.

Mechanism of Action

NSI-189 works by stimulating the growth of new neurons in the hippocampus, an area of the brain that is often smaller in people with depression. It is believed to do this by increasing the expression of genes that are involved in the formation of new neurons, a process known as neurogenesis.

Clinical Trials

NSI-189 has undergone several phases of clinical trials. In Phase 1 trials, it was found to be safe and well-tolerated in healthy volunteers. In Phase 2 trials, it showed promise in treating major depressive disorder, with patients reporting significant improvements in their symptoms.

Potential Uses

While NSI-189 is primarily being developed as a treatment for major depressive disorder, its ability to stimulate neurogenesis suggests that it may also have potential uses in other conditions that involve the loss of neurons, such as Alzheimer's disease and Parkinson's disease.

See Also

• Neuralstem, Inc.
• Neurogenesis
• Major depressive disorder
• Alzheimer's disease
• Parkinson's disease